Department of Dermatology, Faculty of Medicine, University of Tokyo, Japan.
J Immunol. 2010 May 1;184(9):4637-45. doi: 10.4049/jimmunol.0901719. Epub 2010 Mar 24.
Although contact hypersensitivity (CHS) has been considered a prototype of T cell-mediated immune reactions, recently a significant contribution of regulatory B cell subsets in the suppression of CHS has been demonstrated. CD22, one of the sialic acid-binding immunoglobulin-like lectins, is a B cell-specific molecule that negatively regulates BCR signaling. To clarify the roles of B cells in CHS, CHS in CD22(-/-) mice was investigated. CD22(-/-) mice showed delayed recovery from CHS reactions compared with that of wild-type mice. Transfer of wild-type peritoneal B-1a cells reversed the prolonged CHS reaction seen in CD22(-/-) mice, and this was blocked by the simultaneous injection with IL-10 receptor Ab. Although CD22(-/-) peritoneal B-1a cells were capable of producing IL-10 at wild-type levels, i.p. injection of differentially labeled wild-type/CD22(-/-) B cells demonstrated that a smaller number of CD22(-/-) B cells resided in lymphoid organs 5 d after CHS elicitation, suggesting a defect in survival or retention in activated CD22(-/-) peritoneal B-1 cells. Thus, our study reveals a regulatory role for peritoneal B-1a cells in CHS. Two distinct regulatory B cell subsets cooperatively inhibit CHS responses. Although splenic CD1d(hi)CD5(+) B cells have a crucial role in suppressing the acute exacerbating phase of CHS, peritoneal B-1a cells are likely to suppress the late remission phase as "regulatory B cells." CD22 deficiency results in disturbed CHS remission by impaired retention or survival of peritoneal B-1a cells that migrate into lymphoid organs.
虽然接触超敏反应 (CHS) 已被认为是 T 细胞介导的免疫反应的原型,但最近已经证明调节性 B 细胞亚群在抑制 CHS 方面有重要作用。CD22 是一种唾液酸结合免疫球蛋白样凝集素,是一种负调控 BCR 信号的 B 细胞特异性分子。为了阐明 B 细胞在 CHS 中的作用,研究了 CD22(-/-) 小鼠的 CHS。与野生型小鼠相比,CD22(-/-) 小鼠的 CHS 反应恢复较慢。向 CD22(-/-) 小鼠体内转移野生型腹腔 B-1a 细胞可逆转其 CHS 反应延长,而同时注射 IL-10 受体 Ab 可阻断该反应。尽管 CD22(-/-) 腹腔 B-1a 细胞能够产生与野生型水平相当的 IL-10,但腹腔注射差异标记的野生型/CD22(-/-) B 细胞表明,在 CHS 激发后 5 天,淋巴器官中存在的 CD22(-/-) B 细胞数量较少,提示活化的 CD22(-/-) 腹腔 B-1a 细胞的存活或保留存在缺陷。因此,我们的研究揭示了腹腔 B-1a 细胞在 CHS 中的调节作用。两种不同的调节性 B 细胞亚群协同抑制 CHS 反应。虽然脾脏 CD1d(hi)CD5(+) B 细胞在抑制 CHS 的急性加剧阶段中具有关键作用,但腹腔 B-1a 细胞可能通过迁移到淋巴器官的腹腔 B-1a 细胞的保留或存活受损来抑制晚期缓解阶段,充当“调节性 B 细胞”。CD22 缺陷导致腹腔 B-1a 细胞的保留或存活受损,从而扰乱 CHS 的缓解。